Rep. Robert Bresnahan, Jr. Purchases Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on May 31st, the Representative disclosed that they had bought between $15,001 and $50,000 in Thermo Fisher Scientific stock on May 15th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zimmer Biomet (NYSE:ZBH) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of WEC Energy Group (NYSE:WEC) on 5/15/2025.
• Purchased $15,001 – $50,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Kraft Heinz (NASDAQ:KHC) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of International Flavors & Fragrances (NYSE:IFF) on 5/15/2025.

Thermo Fisher Scientific Trading Down 1.7%

NYSE:TMO opened at $396.08 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $428.50 and a 200-day simple moving average of $498.72. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The company has a market capitalization of $149.52 billion, a P/E ratio of 23.96, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

Several analysts have commented on TMO shares. Scotiabank decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Finally, Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $607.43.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently modified their holdings of the stock. Semus Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company’s stock worth $245,000 after buying an additional 18 shares in the last quarter. Evernest Financial Advisors LLC increased its position in shares of Thermo Fisher Scientific by 4.0% during the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company’s stock worth $271,000 after purchasing an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC raised its stake in Thermo Fisher Scientific by 2.7% in the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 20 shares during the last quarter. Cassaday & Co Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 0.9% in the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company’s stock valued at $1,189,000 after purchasing an additional 20 shares in the last quarter. Finally, Callan Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company’s stock worth $402,000 after buying an additional 20 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.33% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.